UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended ~~September~~March 3031, ~~2017~~2018

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to ______

Commission File Number 000-54001

PROTECT PHARMACEUTICAL CORPORATION

(Exact name of registrant as specified in its charter)

Nevada

27-1877179

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

954876 ~~Merrick~~Cecile ~~Way~~Avenue, ~~Third~~Las ~~Floor~~Vegas, ~~Coral~~NV ~~Gables, Florida 33143~~89115

(Address of principal executive offices)

(954) 292-0033

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [ ] No [X]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [ ] No [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated file [ ] Accelerated filer [ ] Non-Accelerated filer [ ] Smaller reporting company [X] ~~Emerging growth company [ ]~~

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [X] No [ ]

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date.

Class		Outstanding as of ~~September~~March 3031, ~~2017~~2018
Common Stock, $0.005 par value		1,111,460	~~1,111,460~~

TABLE OF CONTENTS

PART I.	FINANCIAL INFORMATION
	ITEM 1.	Financial Statements
		Condensed Balance sheets as of September 30, 2017 (unaudited) and December 31, 2016	4
		Condensed Balance Sheets as of March 31, 2018 (unaudited) and December 31, 2017	4
		Condensed Statements of operations for the three and nine months ended September 30, 2017 and 2016 (unaudited)	5
		Condensed Statements of Operations for the three months ended March 31, 2018 and 2017 (unaudited)	5
		Condensed Statements of cash flows for the nine months ended September 30, 2017 and 2016 (unaudited)	6
		Condensed Statements of Cash Flows for the three months ended March 31, 2018 and 2017 (unaudited)	6
		Notes to condensed financial statements September 30, 2017 (unaudited)	7-8
		Notes to condensed financial statements as of March 31, 2018 (unaudited)	7-9
	ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	910-1213
	ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	1213
	ITEM 4.	Controls and Procedures	1213
PART II.	OTHER INFORMATION
	ITEM 1.	Legal Proceedings	1315
	ITEM 1A.	Risk Factors	1315
	ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	1315
	ITEM 3.	Defaults Upon Senior Securities	1315
	ITEM 4.	Mine Safety Disclosures	1315
	ITEM 5.	Other Information	1315
	ITEM 6.	Exhibits	1416
	SIGNATURES		1517

PART I — FINANCIAL INFORMATION

Item 1. Interim Financial Statements and Notes to Interim Financial Statements

Interim Financial Statements and Notes to Interim Financial Statements

General

The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information, the instructions to Form 10-Q, and Article 10 of Regulation S-X. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders’ deficit in conformity with generally accepted accounting principles. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, ~~2016~~2017. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the three months ~~and nine months~~ ended ~~September~~March 3031, ~~2017~~2018 ~~(unaudited)~~ are not necessarily indicative of the results that can be expected for the year ending December 31, ~~2017~~2018.

Protect Pharmaceutical Corporation

Balance Sheets

	September 30, 2017			December 31, 2016
	March 31, 2018			December 31, 2017
	~~(Unaudited)~~	(Unaudited)
ASSETS
Current assets
Current Assets
Cash	$	-100		$	-
Total current assets	$	-		$	-
Total Current Assets	$	100		$	-
TOTAL ASSETS	$	-100		$	-
LIABILITIES
Current liabilities
Current Liabilities
Accounts payable & accrued expenses	$	950		$	9,950
Accounts Payable & Accrued Expenses	$	950		$	950
Related party payables		35,280			10,880
Related Party Payables		35,380			35,280
Interest payable		2,485			-
Interest Payable		9,937			6,211
Total current liabilities	$	38,715		$	20,830
Total Current Liabilities	$	46,267		$	42,441
Long-term liabilities
Long-Term Liabilities
Notes payable, net of debt discounts of $167 and $0, respectively	$	100,833		$	-
Notes Payable	$	101,000		$	101,000
Total long-term liabilities	$	100,833		$	-
Total Long-Term Liabilities	$	101,000		$	101,000
TOTAL LIABILITIES	$	~~139~~147,~~548~~267		$	20143,~~830~~441
STOCKHOLDERS’ DEFICIT
Preferred stock: 10,000,000 shares authorized, at $0.001 par value; 0 shares issued or outstanding as of September 30, 2017 and December 31, 2016	$	-		$	-
Preferred Stock: 110,000,000 shares authorized, at $0.001 par value; 0 shares issued or outstanding as of March 31, 2018 and December 31, 2017	$	-		$	-
Common stock: 100,000,000 shares authorized at $0.005 par value; 1,111,460 shares issued and outstanding as of September 30, 2017 and December 31, 2016		5,557			5,557
Common Stock: 100,000,000 shares authorized at $0.005 par value; 1,111,460 shares issued and outstanding as of March 31, 2018 and December 31, 2017		5,557			5,557
Additional paid-in capital		9,365,612			9,365,612
Additional Paid-In Capital		9,365,612			9,365,612
Accumulated Deficit		(9,~~510~~518,~~717~~336	)		(9,~~391~~514,~~999~~610	)
TOTAL STOCKHOLDERS’ DEFICIT	$	(~~139~~147,~~548~~167	)	$	(20143,~~830~~441	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	-		$	-
TOTAL LIABILITIES AND STOCKHOLDER’S DEFICIT	$	100		$	-

See accompanying notes to the unaudited financial statements.

Protect Pharmaceutical Corporation

Statements of Operations

(Unaudited)

	Three months ended						~~Nine months ended~~
	September 30,						September 30,
	March 31,
	2017			2016			2017			2016
	2018			2017
REVENUES	$	-		$	-		$	-		$	-
OPERATING EXPENSES
Professional fees		-			7,290			115,200			18,225
Professional Fees		-			15,200
Executive compensation		-			1,150			-			4,150
General & Administrative		-			200
General & administrative		-			92			200			287
TOTAL OPERATING EXPENSES	$	-		$	15,400
TOTAL OPERATING EXPENSES	$	-		$	8,532		$	115,400		$	22,662
OPERATING LOSS	$	-		$	(15,400	)
OPERATING LOSS	$	-		$	(8,532	)	$	(115,400	)	$	(22,662	)
Interest Expense		3,726			-
Interest expense		2,985		$	-			3,318			-
LOSS BEFORE TAXES	$	(3,726	)	$	(15,400	)
LOSS BEFORE TAXES	$	(2,985	)	$	(8,532	)	$	(118,718	)	$	(22,662	)
Taxes		-			-
Taxes		-		$	-			-			-
NET LOSS	$	(3,726	)	$	(15,400	)
NET LOSS	$	(2,985	)	$	(8,532	)	$	(118,718	)	$	(22,662	)
BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	$	(0.00	)	$	(0.01	)
BASIC LOSS PER SHARE OF COMMON STOCK	$	(0.00	)	$	(0.01	)	$	(0.11	)	$	(0.02	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING		1,111,460			1,111,460
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING		1,111,460			1,111,460			1,111,460			1,111,460
DILUTED LOSS PER SHARE OF COMMON STOCK	$	(0.00	)	$	(0.01	)
DILUTED LOSS PER SHARE OF COMMON STOCK	$	(0.00	)	$	(0.01	)	$	(0.10	)	$	(0.02	)
DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING		1,358,378			1,111,460
DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING		1,234,919			1,111,460			1,153,065			1,111,460

See accompanying notes to the unaudited financial statements.

Protect Pharmaceutical Corporation

Statements of Cash Flows

(Unaudited)

	For Nine months ended
	For three months ended
	September 30,
	March 31,
	2017			2016
	2018			2017
OPERATING ACTIVITIES
Net Loss	$	(~~118~~3,~~718~~726	)	$	(2215,~~662~~400	)
Adjustments to reconcile net loss to net cash provided by operations:
Adjustments to reconcile Net Loss to Net Cash provided by operations:
Convertible note issued for services		100,833			-
Services contributed by an officer		-			4,150
Changes in operating assets and liabilities:
Accounts payable		(9,000	)		4,399
Accounts Payable		-			(9,000	)
Accounts payable - related party		24,400			-
Accounts Payable - Related Party		100			24,400
Interest Payable		23,~~485~~726			-
Total adjustments to reconcile net loss to net cash provided by operations:		118,718			8,549
Total Adjustments to reconcile Net Loss to Net Cash provided by operations:		3,826			15,400
Net cash used in operating activities	$	-		$	(14,113	)
Net cash provided by operating activities	$	100		$	-
INVESTING ACTIVITIES
Net cash provided by investing activities	$	-		$	-
FINANCING ACTIVITIES
Advances from related party		-			14,151.00
Net cash provided by financing activities	$	-		$	-
Net cash provided by financing activities	$	-		$	14,151
NET CHANGE IN CASH	$	100		$	-
NET CHANGE IN CASH	$	-		$	38
CASH AT BEGINNING OF PERIOD		-			-
CASH AT BEGINNING OF PERIOD		-			7
CASH AT END OF PERIOD		100			-
CASH AT END OF PERIOD		-			45
SUPPLEMENTAL CASH FLOW INFORMATION:
NON-CASH FINANCING ACTIVITIES
Convertible note issued for professional services	$	100,833		$	-

See accompanying notes to the unaudited financial statements.

NOTE 1 - FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows as of ~~September~~March 3031, ~~2017~~2018 and for all periods presented herein, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, ~~2016~~2017 audited financial statements. The results of operations for the period ended ~~September~~March 3031, ~~2017~~2018 (unaudited) are not necessarily indicative of the operating results for the year ended December 31, ~~2017~~2018.

NOTE 2 - GOING CONCERN

The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has ~~does~~limited ~~not have~~ cash orand no other material assets, nor does it have an established source of revenues adequate to cover its operating costs and to allow it to continue as a going concern. It is the intent of the Company to seek a merger with an existing, operating company. In the interim, shareholders of the Company have committed to meeting its minimal operating expenses.

In addition, the inability of ~~The~~the Company to become current in periodic reporting obligations under the federal securities laws during the ~~third~~current quarter limited the information that the Company was able to provide to the public, to investors and to other interested parties, including customers and certain lenders. Furthermore, such inability to become current limited the Company’s ability to use equity incentives to attract, retain and motivate employees. Such inability to become current also restricted the Company’s ability to raise capital through the issuance of equity or debt securities, use equity securities for acquisitions of complementary companies and businesses and engage in other strategic transactions.

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities atas of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basic Loss per Common Share

Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted ~~average~~ average number of common shares during the period. Diluted ~~earnings~~loss per share is calculated by dividing the Company’s net ~~income~~ loss available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There ~~was~~are a246,918 ~~convertible~~such ~~note~~dilutive incommon ~~default~~stock equivalents outstanding as of ~~September~~March 3031, ~~2017~~2018 ~~that was subsequently converted into 246,918 shares of common~~related ~~stock~~to ona ~~December~~convertible ~~11,~~note ~~2018~~in default.

Convertible notes with fixed rate conversion options

The Company may enter into convertible notes, some of which contain, predominantly, fixed rate conversion features, whereby the outstanding principal and accrued interest may be converted by the holder, into common shares at a fixed discount to the market price of the common stock at the time of conversion. This results in a fair value of the convertible note being equal to a fixed monetary amount. The Company records the convertible note liability at its fixed monetary amount by measuring and recording a discount, as applicable, on the ~~Note~~note date with a charge of interest expense in accordance with ASC 480 – “Distinguishing Liabilities from Equity.”

Convertible debt

In July 2017, the FASB issued Accounting Standards Update No. 2017-11 Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 8115) (“ASU 2017-11”), which changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. ASU 2017-11 also clarifies existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, ASU 2017-11 requires entities to present earnings per share (EPS) in accordance with ASC Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. For the Company, ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard on July 1, 2017, and applied it retroactively to the Company’s financial reporting starting on April 1, 2017.

Recent Accounting Pronouncements

Management has considered all other recent accounting pronouncements issued since the last audit of the Company’s financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s financial statements.

NOTE 4 – RELATED-PARTY TRANSACTIONS

The Company has recorded advances from related parties and expenses paid by related parties on behalf of the Company as related party payables. As of ~~September~~March 3031, ~~2017~~2018 (unaudited) and December 31, ~~2016~~2017, the related party payable outstanding balance totaled $35,~~280~~ 380 and $1035,~~880~~280, respectively. These payables are non-interest bearing, unsecured, and are due on demand.

NOTE 5 – CONVERTIBLE ~~NOTES~~NOTE

On April 15, 2017, the Company issued a convertible promissory note (the “Convertible Note”) for $101,000 ($100,000 principal plus a 1% original issue discount) to Trident Cap X Corp. (“Trident”), a Florida Limited Liability Company. The Convertible Note has a maturity date of October 15, 2017, with a 15% default interest rate in the case that the principle is not paid off in full by the maturity date or covenants are not met. In the case of default, the holder has the right to convert all or any portion of the value of the Convertible Note, including unpaid principal, unpaid interest (including default interest), and costs incurred by the holder related to the conversion, into common stock of the Company. The per share conversion price of this Convertible Note into common stock shall be 75% of the lowest traded price of the common stock during the ten consecutive trading days prior to receipt of a notice of conversion from the holder. As of March 31, 2018, interest payable was $9,937.

On August 15, 2017, the Company failed to file Form 10-Q for the three months ended June 30, 2017 with the SEC. As a result, the Convertible Note failed to meet covenant 3.9 “Failure to Comply with the 1934 Act,” triggering an event of default and requiring payment of default interest at an annual rate of 15%. As of September 30, 2017 and December 31, 2016, default interest payable on the Convertible Note was $2,485 and $0, respectively.8

NOTE 6 – SUBSEQUENT EVENTS

~~Conversion~~Default and Conversion of Convertible Note

On August 15, 2017, the Company failed to file Form 10-Q for the three months ended June 30, 2017 with the SEC. As a result, the Convertible Note with Trident failed to meet covenant 3.9 “Failure to Comply with the 1934 Act,” triggering an event of default and requiring payment of default interest at an annual rate of 15%.

On February 8, 2018, Trident assigned the Convertible Note issued by the Company on April 15, 2017 to Global Startup League LLC (“Global”) a Florida Limited Liability Company. As of the date of the assignment, the Company had not paid any principal or interest and the Convertible Note remained in default.

On August 6, 2018, GLOBAL filed a Complaint in the Superior Court for the District of Columbia, styled Global Startup League, LLC v. Protect Pharmaceutical Corporation, alleging that the Company had breached the Convertible Note and owed Global $100,000, plus default interest of at least 15% annually as provided for in the Convertible Note, along with the related attorney’s fees.

We The Company reached a settlement with Global on September 14, 2018, including a release, and had the Company’s transfer agent issue 246,918 shares of Common Stock to Global on December 11, 2018 to satisfy the obligation in full.

8Affirmed and Ratified:

July 7, 2018 - 8-K filed: The Company announced that as of June 30, 2018, as consideration for contractual obligations, and shares of common stock were to be issued. The exact allocation and quantum of such share issuance was adjusted as reflected in the Company's current record of share issuances, which is hereby validated.

July 7, 2018 - 8-K filed: Document July 6, 2018: CEO and Board members were named, but all have since resigned.

October 9, 2018 - Loan: $3,100 from Burton Steer and Associates on October 9, 2017; received in two installments of $2,100 on October 9, 2018 and $1,000 on October 25, 2018; $3,000 was repaid as of December 31, 2018.

November 13, 2018 - SEC 8-K filing: The Board of Directors appointed Una Taylor as a member of the Company’s Board of Directors, effective at the close business as of November 12, 2018. November 12, 2018, Board of Directors issued 1,000,000 shares of preferred stock, Series A, to Una J. Taylor, with each share having 1,000 votes. Yvette Sanchez resigned as an officer of Protect Pharmaceutical Corporation and of the Board of Directors, effective November 13, 2018. Shares and expense reimbursement were authorized for Ms. Taylor. Previous shares from the transactions naming Yvette Sanchez President were sold or otherwise dealt with in the reaffirmed November transactions. Ms. Taylor was also appointed Chief Executive Officer (CEO) on November 13, 2018. CEO employment agreement with Una Taylor on November 14, 2018; $250,000 salary, $50,000 bonus, insurance of $1,983 per month until the end of the 2019 calendar year or until company offers benefits. This action was subsequently ratified by the Board of Directors.

December 10, 2018 - SEC 8-K Filing: Document Date November 28, 2018 - Wajed Salem named to Board of Directors by the existing board, and the Company entered into contract with him.

December 17, 2018 - Loan: $25,000 from Audra M. Hajj to Protect Pharmaceutical.

Misc. dates - Contracts: Engagement or replacement of attorneys or auditors, at the CEO's discretion, with written or other contract terms, again at the discretion of CEO Una J. Taylor.

Disaffirmed and Cancelled, Or Never Came Into Legal Effect:

June 5, 2018 - Change of primary operating entity and business model: The Company did not implement the change of primary operating entity or real estate business model announced in a June 5, 2018 Form 8-K.

September 14, 2018 – Press Release: Company Announces New Business Model; transaction cancelled.

October 20, 2018 - Merger/Acquisition: Tobit Clicks of Tobit LLC; transaction cancelled.

October 2, 2018 - Press Release: Company Joins Tobit Consortium; transaction cancelled.

November 27, 2018 - Private Placement: International Membership Data, LLC, $40 million to be invested by Company; transaction cancelled.

November 28, 2018 - Merger/Acquisition: Target: The Winner's Circle Partners LLC; transaction cancelled.

December 7, 2018 - Press Release: AES and OnliFunds Launch OnliChain focused $250 million Fund. Company option transaction cancelled.

Recent Issuances of Securities:

18,839,918 shares of common stock (including 3,000,000 of restricted shares) and 1,000,000 shares of preferred stock were subsequently issued in 2018 as follows:

September 11, 2018: 10,393,000 shares of common stock to Yvette Sanchez.

November 27, 2018: 3,000,000 restricted shares of common stock were subsequently issued to Eight Dragons Capital.

November 13, 2018: 1,000,000 shares of preferred stock were subsequently issued to Una Taylor.

December 11, 2018: 246,918 shares of common stock were subsequently issued to Global Startup League as payment for the value of a convertible note per a settlement agreement dated September 14, 2018.

December 13, 2018: 200,000 shares of common stock were subsequently issued to Sing for Hope Inc.

As of December 31, 2018, we have outstanding a total of 19,951,378 shares of common stock and 1,000,000 shares of preferred stock.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Following information should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this Form 10-Q.

Forward-Looking and Cautionary Statements

Unless otherwise indicated, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” are to the Company, unless the context requires otherwise. The following discussion and analysis by our management of our financial condition and results of operations should be read in conjunction with our unaudited condensed interim financial statements and the accompanying related notes included in this quarterly report and our audited financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2017 filed with the Securities and Exchange Commission.

Cautionary Statement Regarding Forward-Looking Statements

This report may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we intend that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Any such forward-looking statements would be contained principally in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities and the effects of regulation. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss many of these risks in greater detail in “Risk Factors.” Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this report. You should read this report and the documents that we reference in this report and have filed as exhibits to the report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Additional information concerning these and other risks and uncertainties is contained in our filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2017.

Unless otherwise indicated or the context otherwise requires, all references in this Form 10-Q to “we,” “us,” “our,” “our company,” “Protect” refer to Protect Pharmaceutical Corporation.

Our Ability to Continue as a Going Concern

Our independent registered public accounting firm has issued its report dated ~~March~~February 3127, ~~2017~~2019, in connection with the audit of our annual financial statements as of December 31, ~~2016~~2017, that included an explanatory paragraph describing the existence of ~~conditions~~ conditions that raise substantial doubt about our ability to continue as a going concern and Note 2 to the unaudited financial ~~statements~~ statements for the period ended ~~September~~March 3031, ~~2017~~2018 also describes the existence of conditions that raise substantial doubt about our ~~ability~~ ability to continue as a going concern.

Results of Operations

Three Months Ended ~~September~~March 3031, ~~2017~~2018 and ~~2016~~2017 (unaudited)

We did not realize revenues for the three-month periods ended ~~September~~March 3031, ~~2017~~2018 and ~~2016~~2017 (unaudited). For the three months ended ~~September~~ 30March 31, ~~2017~~2018 (“~~third~~first quarter”), ~~the~~total ~~Company did not have any~~ operating expenses were $0. Interest expense for the ~~third~~three months ended March ~~quarter~~31, 2018 was $23,~~985~~726, with the entire amount related to a convertible note with Trident.

Total operating expenses for the comparable ~~third~~first quarter of ~~2016~~2017 were $815,~~532~~400, consisting of $715,~~290~~200 in professional fees and $~~1,150~~200 in ~~executive compensation, and $92 in~~ general ~~and~~ administrative expenses.

The net loss for the ~~third~~first quarter of ~~2017~~2018 was $23,~~985~~726, (-$0.00 per share; -$0.00 diluted loss per share, including 246,918 shares ~~attributable~~ attributable to convertible note), compared to a net loss of $815,~~532~~400 (-$0.01 per share; -$0.00 diluted loss per share, with no dilutive shares outstanding) for the ~~third~~first quarter of ~~2016~~2017.

1011

Nine Months Ended September 30, 2017 and 2016 (unaudited)

We did not realize revenues for the nine-month periods ended September 30, 2017 and 2016 (unaudited). For the nine months ended September 30, 2017, total operating expenses were $115,400, consisting of professional fees of $115,200 and general & administrative expenses of $200. The increase in professional fees in the first nine months of 2017 is attributable to a contract with Trident for professional services. Interest expense for the nine-month period was $3,318, with the entire amount related to a convertible note with Trident.

Total operating expenses for the comparable period of 2016 were $22,662, consisting of $18,225 in professional fees, $4,150 in executive compensation and $287 in general and administrative expenses.

The net loss for the nine months ended September 30, 2017 was $118,718 (-$0.11 per share; -$0.10 diluted loss per share, including 246,918 shares attributable to convertible note), compared to net loss of $22,662 (-$0.02 per share) for the same period of 2016.

Liquidity and Capital Resources

Total assets were $0100 as of ~~September~~March 3031, ~~2017~~2018 (unaudited) and $0 as of December 31, ~~2016~~2017. Total liabilities at ~~September~~March 3031, ~~2017~~2018 (unaudited) were $~~139~~147,~~548~~267, consisting of $~~100~~101,~~833~~000 in notes payable, $950 in accounts payable and accrued expenses, $35,~~280~~380 in related-party payables, and $29,~~485~~ 937 in ~~Interest~~interest ~~Payable~~payable. At December 31, ~~2016~~2017, total liabilities were $20143,~~830~~441.

Because we currently have limited revenues and cash, for the immediate future we believe we will have to rely on potential advances from stockholders to continue to implement our business activities. There is no assurance that our stockholders will continue indefinitely to provide additional funds or pay our expenses. It is likely the only other source of funding future operations will be through the private sale of our securities, either equity or debt.

At ~~September~~March 3031, ~~2017~~ 2018(unaudited), we had stockholders’ deficit of $~~139~~147,~~548~~167 compared to stockholders’ deficit of $20143,~~830~~ 441 at December 31, ~~2016~~2017.

Plan of Operation

Our current business plan is to contemplate a possible a future business model change by the Company to generate adequate revenue to sustain operations and reduce dependency on shareholder funds. The Company also continues to explore acquisition of or acquisition by either an affiliated entity or an as yet unknown other entity.

Our common stock is currently quoted on the QB tier of the OTC Markets under the ticker symbol “PRTT”.

It is anticipated that business opportunities will come to our attention from various sources, including its officers and directors, its other stockholders, professional advisors such as attorneys and accountants, securities broker-dealers, venture capitalists, members of the financial community, and others who may present unsolicited proposals. We have no plan, understandings, agreements, or commitments with any individual for such person to act as a finder of opportunities for our company.

Because we currently have no cash, it may be necessary for officers, directors or stockholders to advance funds and we will most likely accrue expenses until a funding can be accomplished. Management intends to hold expenses to a minimum and to obtain services on a contingency basis when possible. Further, we expect directors to defer any compensation until such time as we have sufficient funds. We have not yet entered into any arrangements or definitive agreements to use outside advisors or consultants or to raise any capital.

We are currently exploring possible funding sources, but we have not entered into any arrangements or agreements for funding as of this time. If we are unable to raise the necessary funding, our expansion plans will be delayed indefinitely. There can be no assurance that we will be able to raise the funds necessary to carry out our business plan on terms favorable to the company, or at all.

Changes to Company Officers

~~November 17,~~None ~~2017:~~from ~~Jordan~~January ~~Fishman~~1, ~~resigned~~2018 asto ~~Chief~~March ~~Executive~~31 ~~Officer~~2018.

November 17, 2017: Una Taylor was appointed as Chief Executive Officer.

June 1, 2018: Una Taylor resigned as Chief Executive Officer.

June 1, 2018: Yvette Sanchez was appointed President.

November 12, 2018: Yvette Sanchez resigned as President.

November 13, 2018: Una Taylor was appointed as Chief Executive Officer.

Changes to the Board of Directors

None from January 1, 2018 to March 31 2018.

June 1, 2018: Yvette Sanchez was appointed a member of the Board of Directors.

June 5, 2018: Yvette Sanchez removed three members from the Board of Directors by majority vote of the company’s shareholders: Stuart Sandweiss (Director and Audit Committee Chair), Shimson Bandman (Director), and Shedrick W. Daniels (Director). There were no disagreements with these former directors of the Company as to its operations, policies or practices.

November 12, 2018: Una Taylor appointed as a member of the Board of Directors.

November 12, 2018: Yvette Sanchez resigned as a member of the Board of Directors.

Off-balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required under Regulation S-K for “smaller reporting companies.”

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Disclosure and control procedures are also designed to ensure that such information is accumulated and communicated to management, including the chief executive officer and principal accounting officer, to allow timely decisions regarding required disclosures.

As of the end of the period covered by this quarterly report, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment. Based on the evaluation described above, management, including our principal executive officer and principal accounting officer, has concluded that, as of September 30, 2017, our disclosure controls and procedures were not effective.13

As of the end of the period covered by this quarterly report, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment. Based on the evaluation described above, management, including our principal executive officer and principal accounting officer, has concluded that, as of March 31, 2018, our disclosure controls and procedures were not effective.

Changes in Internal Control Over Financial Reporting

Management has evaluated whether any change in our internal control over financial reporting occurred during the ~~third~~first quarter of fiscal ~~2017~~2018. Based on its evaluation, management, including the chief executive officer ~~and principal accounting officer~~, has concluded that there has been no change in our internal control over financial reporting during the ~~third~~first quarter of fiscal ~~2017~~2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

1214

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

There are no material pending legal proceedings to which we are a party or to which any of our property is subject and, to the best of our knowledge, no such actions against us are contemplated or threatened as of the time of filing. Note the discussion above at Note 6 to Part 1 and in Item 3, below, concerning a lawsuit which was pending during the first quarter of fiscal 2018, and was settled in September, 2018.

Item 1A. Risk Factors

Not required under Regulation S-K for “smaller reporting companies.”

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None from January 1, 2018 to March 31 2018.

Item 3. Defaults Upon Senior Securities

On April 15, 2017, the Company issued a convertible promissory note (the “Convertible Note”) for $101,000 ($100,000 principal plus a 1% original issue discount) to Trident Cap X Corp. (“Trident”), a Florida Limited Liability Company. The Convertible Note has a maturity date of October 15, 2017, with a 15% default interest rate in the case that the principle is not paid off in full by the maturity date. In the case of default, the holder has the right to convert all or any portion of the value of the Convertible Note, including unpaid principal, unpaid interest (including default interest), and costs incurred by the holder related to the conversion, into common stock of the Company. The per share conversion price of this Convertible Note into common stock shall be 75% of the lowest traded price of the common stock during the ten consecutive trading days prior to receipt of a notice of conversion from the holder.

On August 15, 2017, the Company failed to file the Form 10-Q for the three months ended June 30, 2017 with the SEC. As a result, the Convertible Note failed to meet covenant 3.9 “Failure to Comply with the 1934 Act,” triggering an event of default.

On February 8, 2018, Trident assigned the Convertible Note to Global Startup League LLC (“Global”) a Florida Limited Liability Company. As of the date of the assignment, the Company had not paid any principal or interest. As a result, the Convertible Note was in default.

We reached a settlement with Global on September 14, 2018, including a release, and had PRTT’s transfer agent issue 246,918 shares of Common Stock to Global on December 11, 2018 to satisfy the obligation.

Item 4. Mine Safety Disclosures

This Item is not applicable.

Item 5. Other Information

	●	8-k filed July 7, 2017, announced that as of June 30, 2017, as consideration for contractual obligations, shares of our common stock were to be issued. Actual issuances were different and not as then proposed, but are reflected in the Company’s current record of share issuances, which is hereby validated.
	●	8-k filed July 7, 2017, document July 6, 2017: CEO and Board members changes.

None.

1315

Item 6. Exhibits

Exhibit No.		Exhibit Name

3.1*		Articles of Incorporation
3.2*		Certificate of Amendment – Capitalization Change
3.3*		Certificate of Amendment – Name Change 2006
3.4*		Certificate of Amendment – Name Change 2010
3.5*		By-Laws
4.1*		Instrument defining rights of holders – Specimen Stock Certificate
4.2**		Certificate of Amendment – Share Authorization
14.1***		Financial Code of Ethics
31.1		Certificate of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley act of 2002
31.2		Certificate of Principal Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley act of 2002
32.1		Certificate of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley act of 2002
32.2		Certificate of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley act of 2002
101 INS		XBRL Instance Document
101 SCH		XBRL Taxonomy Extension Schema Document
101 CAL		XBRL Taxonomy Calculation Linkbase Document
101 DEF		XBRL Taxonomy Extension Definition Linkbase Document
101 LAB		XBRL Taxonomy Labels Linkbase Document
101 PRE		XBRL Taxonomy Presentation Linkbase Document

*	Previously filed as exhibit to Form 10 filed on June 8, 2010.
**	Previously filed as exhibit to Form 10-Q filed on February 7, 2019.
***	Previously filed as exhibit to Form 8-K filed on September 20, 2016.

1416

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Protect Pharmaceutical Corporation
Date: February 8, 2019	By:	/s/ Una Taylor
Date: February 28, 2019	By:	/s/ Una Taylor
		Una Taylor
		Chief Executive Officer and Director Principal Accounting Officer
		Chief Executive Officer and Director
		Principal Executive Officer
		Principal Accounting Officer

1517

Filing Compare · PROTECT PHARMACEUTICAL Corp